Evidence map›Paper›PMID 38496658›Full record

ArticlebioRxiv : the preprint server for biology2024

Crimean-Congo Hemorrhagic Fever Survivors Elicit Protective Non-Neutralizing Antibodies that Target 11 Overlapping Regions on Viral Glycoprotein GP38.

Olivia S Shin, Stephanie R Monticelli, Christy K Hjorth, Vladlena Hornet, Michael Doyle, Dafna Abelson, Ana I Kuehne, Albert Wang, Russell R Bakken, Akaash Mishra and 17 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 3 countries.

Olivia S ShinAdimab, LLC, Lebanon, NH 03766, USA.
Stephanie R MonticelliU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
Christy K HjorthDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
Vladlena HornetAdimab, LLC, Lebanon, NH 03766, USA.
Michael DoyleAdimab, LLC, Lebanon, NH 03766, USA.
Dafna AbelsonMapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
Ana I KuehneU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
Albert WangDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Russell R BakkenU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
Akaash MishraDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
Marissa MiddlecampMapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
Elizabeth ChampneyAdimab, LLC, Lebanon, NH 03766, USA.
Lauran StuartMapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
Daniel P MaurerAdimab, LLC, Lebanon, NH 03766, USA.
Jiannan LiAdimab, LLC, Lebanon, NH 03766, USA.
Jacob BerriganDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Jennifer BarajasMapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
Stephen BalinandiUganda Virus Research Institute, Entebbe, Uganda.
Julius J LutwamaUganda Virus Research Institute, Entebbe, Uganda.
Leslie LobelDepartment of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Larry ZeitlinMapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.
Laura M WalkerAdimab, LLC, Lebanon, NH 03766, USA.
John M DyeU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
Kartik ChandranDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Andrew S HerbertU.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
Noel T PauliAdimab, LLC, Lebanon, NH 03766, USA.
Jason S McLellanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
Adimab (United States) · USUnited States Army Medical Research Institute of Infectious Diseases · USAlbert Einstein College of Medicine · USThe University of Texas at Austin · USUganda Virus Research Institute · UGBen-Gurion University of the Negev · IL

Funding

Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral ThreatsU19AI142777 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI CHANDRAN, KARTIK · 2019 to 2023
$21.9M
Structure-based Vaccine Design for CCHFVR01AI152246 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI CHANDRAN, KARTIK, MCLELLAN, JASON SCOTT · 2020 to 2024
$2.2M
NIAID NIH HHS R01 AI152246NIAID NIH HHS U19 AI142777
6 · The paper itself

Abstract

Crimean-Congo hemorrhagic fever virus can cause lethal disease in humans yet there are no approved medical countermeasures. Viral glycoprotein GP38, unique to

Indexed as

antibody therapeuticsCCHFVCrimean-Congo hemorrhagic fever virusGP38human monoclonal antibodyNairoviridaetickborneviral glycoprotein

Identifiers

PMID38496658
PMCPMC10942344
OpenAlexW4392502377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.